Annual Stockholder Meeting Results and Director Elections

Pyxis Oncology, Inc. held its Annual Meeting of Stockholders on June 15, 2026, in a virtual format. The company reported that 47,302,035 shares were present or represented by proxy, constituting a quorum. Stockholders voted on two key proposals. First, they elected three Class II directors: Mr. Thomas Civik (27,341,415 for, 1,981,857 withheld), Dr. Freda Lewis-Hall, M.D. (19,188,755 for, 10,134,517 withheld), and Mr. Michael A. Metzger (26,521,575 for, 2,801,697 withheld). All three directors will serve until the 2029 Annual Meeting. Second, stockholders ratified the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for fiscal year 2026, with 46,203,257 votes for, 1,076,997 against, and 21,781 abstentions. The record date for the meeting was April 20, 2026, with 62,855,464 shares outstanding and entitled to vote.